EP Patent

EP3986479A1 — Anti-ctla4 conjugates

Assigned to Ascendis Pharma Oncology Division AS · Expires 2022-04-27 · 4y expired

What this patent protects

The present invention relates to an anti-CTLA4 conjugate or a pharmaceutically acceptable salt thereof, wherein said conjugate comprises a plurality of anti-CTLA4 moieties -D covalently conjugated via at least one moiety -L1-L2 - to a polymeric moiety Z, wherein -L1 - is covalent…

USPTO Abstract

The present invention relates to an anti-CTLA4 conjugate or a pharmaceutically acceptable salt thereof, wherein said conjugate comprises a plurality of anti-CTLA4 moieties -D covalently conjugated via at least one moiety -L1-L2 - to a polymeric moiety Z, wherein -L1 - is covalently and reversibly conjugated to -D and -L2 - is covalently conjugated to Z and wherein -L1- is a linker moiety and -L2- is a chemical bond or a spacer moiety; and related aspects.

Drugs covered by this patent

Patent Metadata

Patent number
EP3986479A1
Jurisdiction
EP
Classification
—
Expires
2022-04-27
Drug substance claim
No
Drug product claim
No
Assignee
Ascendis Pharma Oncology Division AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.